Phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma; PRIMER trial
Latest Information Update: 27 Apr 2020
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Acronyms PRIMER
- 13 Apr 2019 As the early termination criterion (less than one responder) was fulfilled during the first stage, the study was deemed futile and was terminated as per results published in the European Journal of Cancer
- 13 Apr 2019 Results published in the European Journal of Cancer
- 03 Oct 2017 Status changed from suspended to active, no longer recruiting.